Loading...
XNAS
TARA
Market cap162mUSD
Jul 09, Last price  
4.20USD
1D
2.19%
1Q
-15.32%
Jan 2017
-94.47%
IPO
-98.95%
Name

Protara Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TARA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
42.72%
Rev. gr., 5y
%
Revenues
0k
002,948,00000000000000
Net income
-57m
L+28.80%
-7,970,000-7,912,000-3,342,000-21,377,000-28,526,000-29,964,000-25,437,000-14,992,000-33,978,000-47,252,000-65,952,000-40,420,000-44,596,000-57,439,000
CFO
-56m
L+57.41%
-8,234,000-6,703,000-9,990,000-17,566,000-23,687,000-22,352,000-23,233,000-15,646,000-23,407,000-34,502,000-26,457,000-37,557,000-35,808,000-56,365,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
URL
https://protaratx.com/
IPO date
Oct 22, 2014
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT